nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—coronary artery disease—metabolic syndrome X	0.303	0.411	CtDrD
Valsartan—type 2 diabetes mellitus—metabolic syndrome X	0.252	0.343	CtDrD
Valsartan—ALB—metabolic syndrome X	0.195	1	CbGaD
Valsartan—hypertension—metabolic syndrome X	0.18	0.245	CtDrD
Valsartan—AGTR1—artery—metabolic syndrome X	0.00194	0.194	CbGeAlD
Valsartan—AGTR1—endothelium—metabolic syndrome X	0.00164	0.164	CbGeAlD
Valsartan—AGTR1—blood vessel—metabolic syndrome X	0.00151	0.151	CbGeAlD
Valsartan—SLCO1B3—liver—metabolic syndrome X	0.000686	0.0688	CbGeAlD
Valsartan—AGTR1—cardiovascular system—metabolic syndrome X	0.000673	0.0674	CbGeAlD
Valsartan—Renal impairment—Metformin—metabolic syndrome X	0.000658	0.0369	CcSEcCtD
Valsartan—AGTR1—kidney—metabolic syndrome X	0.000658	0.066	CbGeAlD
Valsartan—SLCO1B1—kidney—metabolic syndrome X	0.000628	0.0629	CbGeAlD
Valsartan—AGTR1—adipose tissue—metabolic syndrome X	0.000593	0.0595	CbGeAlD
Valsartan—Abdominal pain upper—Metformin—metabolic syndrome X	0.000572	0.0321	CcSEcCtD
Valsartan—Cramp muscle—Metformin—metabolic syndrome X	0.000564	0.0316	CcSEcCtD
Valsartan—Neutropenia—Metformin—metabolic syndrome X	0.000506	0.0284	CcSEcCtD
Valsartan—Upper respiratory tract infection—Metformin—metabolic syndrome X	0.000503	0.0282	CcSEcCtD
Valsartan—Infestation—Metformin—metabolic syndrome X	0.000483	0.0271	CcSEcCtD
Valsartan—Infestation NOS—Metformin—metabolic syndrome X	0.000483	0.0271	CcSEcCtD
Valsartan—Rhinitis—Metformin—metabolic syndrome X	0.000434	0.0244	CcSEcCtD
Valsartan—Hepatitis—Metformin—metabolic syndrome X	0.000433	0.0243	CcSEcCtD
Valsartan—Connective tissue disorder—Metformin—metabolic syndrome X	0.000426	0.0239	CcSEcCtD
Valsartan—AGTR1—liver—metabolic syndrome X	0.000416	0.0417	CbGeAlD
Valsartan—Cardiac disorder—Metformin—metabolic syndrome X	0.000402	0.0226	CcSEcCtD
Valsartan—SLCO1B1—liver—metabolic syndrome X	0.000397	0.0398	CbGeAlD
Valsartan—Angiopathy—Metformin—metabolic syndrome X	0.000393	0.022	CcSEcCtD
Valsartan—Immune system disorder—Metformin—metabolic syndrome X	0.000391	0.022	CcSEcCtD
Valsartan—Mediastinal disorder—Metformin—metabolic syndrome X	0.000391	0.0219	CcSEcCtD
Valsartan—Malnutrition—Metformin—metabolic syndrome X	0.000377	0.0212	CcSEcCtD
Valsartan—Flatulence—Metformin—metabolic syndrome X	0.000372	0.0208	CcSEcCtD
Valsartan—Dysgeusia—Metformin—metabolic syndrome X	0.000369	0.0207	CcSEcCtD
Valsartan—Muscle spasms—Metformin—metabolic syndrome X	0.000363	0.0203	CcSEcCtD
Valsartan—Vision blurred—Metformin—metabolic syndrome X	0.000356	0.0199	CcSEcCtD
Valsartan—Syncope—Metformin—metabolic syndrome X	0.000338	0.019	CcSEcCtD
Valsartan—Palpitations—Metformin—metabolic syndrome X	0.000333	0.0187	CcSEcCtD
Valsartan—Loss of consciousness—Metformin—metabolic syndrome X	0.000332	0.0186	CcSEcCtD
Valsartan—CYP2C9—cardiovascular system—metabolic syndrome X	0.000324	0.0325	CbGeAlD
Valsartan—Chest pain—Metformin—metabolic syndrome X	0.000321	0.018	CcSEcCtD
Valsartan—Myalgia—Metformin—metabolic syndrome X	0.000321	0.018	CcSEcCtD
Valsartan—ALB—liver—metabolic syndrome X	0.000321	0.0322	CbGeAlD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Metformin—metabolic syndrome X	0.000319	0.0179	CcSEcCtD
Valsartan—Oedema—Metformin—metabolic syndrome X	0.000308	0.0173	CcSEcCtD
Valsartan—Infection—Metformin—metabolic syndrome X	0.000306	0.0172	CcSEcCtD
Valsartan—Shock—Metformin—metabolic syndrome X	0.000303	0.017	CcSEcCtD
Valsartan—Nervous system disorder—Metformin—metabolic syndrome X	0.000302	0.0169	CcSEcCtD
Valsartan—Thrombocytopenia—Metformin—metabolic syndrome X	0.000301	0.0169	CcSEcCtD
Valsartan—Skin disorder—Metformin—metabolic syndrome X	0.000299	0.0168	CcSEcCtD
Valsartan—Losartan—ACE—metabolic syndrome X	0.000298	0.709	CrCbGaD
Valsartan—Anorexia—Metformin—metabolic syndrome X	0.000293	0.0165	CcSEcCtD
Valsartan—Hypotension—Metformin—metabolic syndrome X	0.000288	0.0161	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Metformin—metabolic syndrome X	0.000281	0.0157	CcSEcCtD
Valsartan—Paraesthesia—Metformin—metabolic syndrome X	0.000276	0.0155	CcSEcCtD
Valsartan—Dyspnoea—Metformin—metabolic syndrome X	0.000275	0.0154	CcSEcCtD
Valsartan—Somnolence—Metformin—metabolic syndrome X	0.000274	0.0153	CcSEcCtD
Valsartan—Dyspepsia—Metformin—metabolic syndrome X	0.000271	0.0152	CcSEcCtD
Valsartan—Decreased appetite—Metformin—metabolic syndrome X	0.000268	0.015	CcSEcCtD
Valsartan—Gastrointestinal disorder—Metformin—metabolic syndrome X	0.000266	0.0149	CcSEcCtD
Valsartan—Fatigue—Metformin—metabolic syndrome X	0.000265	0.0149	CcSEcCtD
Valsartan—Constipation—Metformin—metabolic syndrome X	0.000263	0.0148	CcSEcCtD
Valsartan—Gastrointestinal pain—Metformin—metabolic syndrome X	0.000252	0.0141	CcSEcCtD
Valsartan—Urticaria—Metformin—metabolic syndrome X	0.000245	0.0137	CcSEcCtD
Valsartan—Abdominal pain—Metformin—metabolic syndrome X	0.000243	0.0136	CcSEcCtD
Valsartan—Asthenia—Metformin—metabolic syndrome X	0.000221	0.0124	CcSEcCtD
Valsartan—Pruritus—Metformin—metabolic syndrome X	0.000218	0.0122	CcSEcCtD
Valsartan—Diarrhoea—Metformin—metabolic syndrome X	0.000211	0.0118	CcSEcCtD
Valsartan—Dizziness—Metformin—metabolic syndrome X	0.000204	0.0114	CcSEcCtD
Valsartan—CYP2C9—liver—metabolic syndrome X	0.0002	0.0201	CbGeAlD
Valsartan—Vomiting—Metformin—metabolic syndrome X	0.000196	0.011	CcSEcCtD
Valsartan—Rash—Metformin—metabolic syndrome X	0.000194	0.0109	CcSEcCtD
Valsartan—Dermatitis—Metformin—metabolic syndrome X	0.000194	0.0109	CcSEcCtD
Valsartan—Headache—Metformin—metabolic syndrome X	0.000193	0.0108	CcSEcCtD
Valsartan—Nausea—Metformin—metabolic syndrome X	0.000183	0.0103	CcSEcCtD
Valsartan—Losartan—ALB—metabolic syndrome X	0.000122	0.291	CrCbGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—TRIB3—metabolic syndrome X	3.03e-05	0.000732	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CETP—metabolic syndrome X	3.02e-05	0.00073	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	3.02e-05	0.000729	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOC3—metabolic syndrome X	2.98e-05	0.000721	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	2.94e-05	0.00071	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AGT—metabolic syndrome X	2.92e-05	0.000706	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—APOA1—metabolic syndrome X	2.91e-05	0.000703	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SCARB1—metabolic syndrome X	2.89e-05	0.000699	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—metabolic syndrome X	2.89e-05	0.000698	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	2.88e-05	0.000697	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—APOB—metabolic syndrome X	2.87e-05	0.000694	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HDAC3—metabolic syndrome X	2.84e-05	0.000687	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—metabolic syndrome X	2.84e-05	0.000687	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	2.81e-05	0.000681	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SREBF1—metabolic syndrome X	2.81e-05	0.000679	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPA—metabolic syndrome X	2.78e-05	0.000672	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—G6PD—metabolic syndrome X	2.77e-05	0.000671	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	2.74e-05	0.000662	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMGCR—metabolic syndrome X	2.73e-05	0.00066	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GOT2—metabolic syndrome X	2.73e-05	0.00066	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HDAC3—metabolic syndrome X	2.71e-05	0.000655	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LIPC—metabolic syndrome X	2.7e-05	0.000652	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G6—metabolic syndrome X	2.69e-05	0.000651	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HTR2C—metabolic syndrome X	2.69e-05	0.00065	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOC3—metabolic syndrome X	2.68e-05	0.000648	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—metabolic syndrome X	2.68e-05	0.000647	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—metabolic syndrome X	2.66e-05	0.000644	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AGT—metabolic syndrome X	2.65e-05	0.000641	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPA—metabolic syndrome X	2.65e-05	0.00064	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GCKR—metabolic syndrome X	2.65e-05	0.00064	CbGpPWpGaD
Valsartan—ALB—Metabolism—FMO3—metabolic syndrome X	2.63e-05	0.000637	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CYBA—metabolic syndrome X	2.6e-05	0.00063	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CETP—metabolic syndrome X	2.6e-05	0.000629	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—GCK—metabolic syndrome X	2.56e-05	0.00062	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PLA2G6—metabolic syndrome X	2.56e-05	0.00062	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GHRL—metabolic syndrome X	2.55e-05	0.000616	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	2.54e-05	0.000615	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA5—metabolic syndrome X	2.54e-05	0.000613	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—SCARB1—metabolic syndrome X	2.49e-05	0.000603	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—TRIB3—metabolic syndrome X	2.48e-05	0.000599	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CETP—metabolic syndrome X	2.47e-05	0.000598	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	2.46e-05	0.000596	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	2.46e-05	0.000595	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ABCA1—metabolic syndrome X	2.43e-05	0.000588	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC2A4—metabolic syndrome X	2.43e-05	0.000588	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IGF1—metabolic syndrome X	2.43e-05	0.000587	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PPARA—metabolic syndrome X	2.42e-05	0.000585	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—SREBF1—metabolic syndrome X	2.42e-05	0.000585	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	2.41e-05	0.000584	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CNR1—metabolic syndrome X	2.41e-05	0.000584	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	2.39e-05	0.000577	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TRIB3—metabolic syndrome X	2.36e-05	0.00057	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GOT1—metabolic syndrome X	2.36e-05	0.00057	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GGT1—metabolic syndrome X	2.36e-05	0.00057	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HMGCR—metabolic syndrome X	2.35e-05	0.000569	CbGpPWpGaD
Valsartan—ALB—Metabolism—EPHX2—metabolic syndrome X	2.35e-05	0.000567	CbGpPWpGaD
Valsartan—ALB—Metabolism—MLXIPL—metabolic syndrome X	2.35e-05	0.000567	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINE1—metabolic syndrome X	2.31e-05	0.000558	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—metabolic syndrome X	2.29e-05	0.000554	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—APOA1—metabolic syndrome X	2.27e-05	0.000549	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—metabolic syndrome X	2.21e-05	0.000534	CbGpPWpGaD
Valsartan—ALB—Metabolism—G6PC2—metabolic syndrome X	2.21e-05	0.000533	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—metabolic syndrome X	2.19e-05	0.00053	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL2—metabolic syndrome X	2.18e-05	0.000528	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FMO3—metabolic syndrome X	2.15e-05	0.000521	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CETP—metabolic syndrome X	2.13e-05	0.000515	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAMPT—metabolic syndrome X	2.12e-05	0.000512	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	2.1e-05	0.000509	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LIPC—metabolic syndrome X	2.1e-05	0.000508	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GCK—metabolic syndrome X	2.1e-05	0.000508	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—ABCA1—metabolic syndrome X	2.1e-05	0.000507	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOC3—metabolic syndrome X	2.09e-05	0.000505	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—metabolic syndrome X	2.04e-05	0.000493	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GGT1—metabolic syndrome X	2.03e-05	0.000491	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CETP—metabolic syndrome X	2.03e-05	0.00049	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOB—metabolic syndrome X	2e-05	0.000484	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC2A4—metabolic syndrome X	1.99e-05	0.000482	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—SREBF1—metabolic syndrome X	1.98e-05	0.000479	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF2—metabolic syndrome X	1.97e-05	0.000477	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF2—metabolic syndrome X	1.95e-05	0.000472	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PLA2G4A—metabolic syndrome X	1.95e-05	0.00047	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SCARB1—metabolic syndrome X	1.94e-05	0.00047	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—metabolic syndrome X	1.93e-05	0.000466	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EPHX2—metabolic syndrome X	1.92e-05	0.000464	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MLXIPL—metabolic syndrome X	1.92e-05	0.000464	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOB—metabolic syndrome X	1.92e-05	0.000463	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—LPL—metabolic syndrome X	1.91e-05	0.000462	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOB—metabolic syndrome X	1.89e-05	0.000458	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	1.89e-05	0.000457	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SREBF1—metabolic syndrome X	1.89e-05	0.000456	CbGpPWpGaD
Valsartan—ALB—Metabolism—FABP4—metabolic syndrome X	1.88e-05	0.000454	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL5—metabolic syndrome X	1.87e-05	0.000452	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PLA2G4A—metabolic syndrome X	1.86e-05	0.000451	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLA2G4A—metabolic syndrome X	1.84e-05	0.000445	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GOT2—metabolic syndrome X	1.83e-05	0.000444	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMGCR—metabolic syndrome X	1.83e-05	0.000444	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LPL—metabolic syndrome X	1.83e-05	0.000442	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CD36—metabolic syndrome X	1.81e-05	0.000439	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—G6PC2—metabolic syndrome X	1.81e-05	0.000437	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—metabolic syndrome X	1.8e-05	0.000435	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSD11B1—metabolic syndrome X	1.78e-05	0.00043	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	1.72e-05	0.000417	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CD36—metabolic syndrome X	1.72e-05	0.000415	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—metabolic syndrome X	1.72e-05	0.000415	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARA—metabolic syndrome X	1.69e-05	0.000408	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	1.68e-05	0.000405	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—metabolic syndrome X	1.66e-05	0.000402	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	1.65e-05	0.0004	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	1.65e-05	0.000398	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOB—metabolic syndrome X	1.64e-05	0.000396	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCA1—metabolic syndrome X	1.64e-05	0.000395	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC2A4—metabolic syndrome X	1.64e-05	0.000395	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—metabolic syndrome X	1.63e-05	0.000395	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—metabolic syndrome X	1.6e-05	0.000387	CbGpPWpGaD
Valsartan—ALB—Metabolism—G6PD—metabolic syndrome X	1.59e-05	0.000383	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GOT1—metabolic syndrome X	1.58e-05	0.000383	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GGT1—metabolic syndrome X	1.58e-05	0.000383	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOA1—metabolic syndrome X	1.58e-05	0.000383	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—metabolic syndrome X	1.57e-05	0.000378	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	1.56e-05	0.000378	CbGpPWpGaD
Valsartan—ALB—Metabolism—HDAC3—metabolic syndrome X	1.55e-05	0.000374	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—FABP4—metabolic syndrome X	1.54e-05	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—metabolic syndrome X	1.53e-05	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—metabolic syndrome X	1.53e-05	0.000371	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOA1—metabolic syndrome X	1.52e-05	0.000367	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCKR—metabolic syndrome X	1.51e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPA—metabolic syndrome X	1.51e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOA1—metabolic syndrome X	1.5e-05	0.000362	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G6—metabolic syndrome X	1.46e-05	0.000354	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—metabolic syndrome X	1.46e-05	0.000352	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD11B1—metabolic syndrome X	1.46e-05	0.000352	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	1.45e-05	0.000352	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA5—metabolic syndrome X	1.45e-05	0.00035	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—metabolic syndrome X	1.41e-05	0.000341	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	1.41e-05	0.00034	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—metabolic syndrome X	1.39e-05	0.000337	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—metabolic syndrome X	1.38e-05	0.000334	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	1.38e-05	0.000334	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—metabolic syndrome X	1.37e-05	0.000332	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS1—metabolic syndrome X	1.37e-05	0.000331	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—INS—metabolic syndrome X	1.37e-05	0.000331	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.36e-05	0.00033	CbGpPWpGaD
Valsartan—ALB—Metabolism—TRIB3—metabolic syndrome X	1.35e-05	0.000326	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—metabolic syndrome X	1.35e-05	0.000326	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOB—metabolic syndrome X	1.34e-05	0.000325	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INS—metabolic syndrome X	1.31e-05	0.000317	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PLA2G4A—metabolic syndrome X	1.31e-05	0.000316	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—G6PD—metabolic syndrome X	1.3e-05	0.000314	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOA1—metabolic syndrome X	1.3e-05	0.000314	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—metabolic syndrome X	1.29e-05	0.000312	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—metabolic syndrome X	1.28e-05	0.00031	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—metabolic syndrome X	1.28e-05	0.00031	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—metabolic syndrome X	1.27e-05	0.000306	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HDAC3—metabolic syndrome X	1.27e-05	0.000306	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—metabolic syndrome X	1.25e-05	0.000303	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—metabolic syndrome X	1.25e-05	0.000303	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPA—metabolic syndrome X	1.24e-05	0.000299	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCKR—metabolic syndrome X	1.24e-05	0.000299	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD36—metabolic syndrome X	1.22e-05	0.000295	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAMPT—metabolic syndrome X	1.21e-05	0.000292	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—metabolic syndrome X	1.2e-05	0.000291	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	1.2e-05	0.000291	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCK—metabolic syndrome X	1.2e-05	0.00029	CbGpPWpGaD
Valsartan—ALB—Metabolism—LIPC—metabolic syndrome X	1.2e-05	0.00029	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—metabolic syndrome X	1.2e-05	0.00029	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G6—metabolic syndrome X	1.2e-05	0.00029	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOC3—metabolic syndrome X	1.19e-05	0.000289	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—metabolic syndrome X	1.19e-05	0.000288	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—metabolic syndrome X	1.19e-05	0.000288	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA5—metabolic syndrome X	1.19e-05	0.000287	CbGpPWpGaD
Valsartan—ALB—Metabolism—CETP—metabolic syndrome X	1.16e-05	0.00028	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—metabolic syndrome X	1.15e-05	0.000279	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—metabolic syndrome X	1.15e-05	0.000278	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—metabolic syndrome X	1.14e-05	0.000275	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—metabolic syndrome X	1.13e-05	0.000274	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—metabolic syndrome X	1.13e-05	0.000273	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—metabolic syndrome X	1.12e-05	0.00027	CbGpPWpGaD
Valsartan—ALB—Metabolism—SCARB1—metabolic syndrome X	1.11e-05	0.000268	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TRIB3—metabolic syndrome X	1.1e-05	0.000267	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—metabolic syndrome X	1.1e-05	0.000265	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—metabolic syndrome X	1.1e-05	0.000265	CbGpPWpGaD
Valsartan—ALB—Metabolism—SREBF1—metabolic syndrome X	1.08e-05	0.00026	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—metabolic syndrome X	1.08e-05	0.00026	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA1—metabolic syndrome X	1.06e-05	0.000257	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMGCR—metabolic syndrome X	1.05e-05	0.000253	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT2—metabolic syndrome X	1.05e-05	0.000253	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—metabolic syndrome X	1.01e-05	0.000245	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAMPT—metabolic syndrome X	9.89e-06	0.000239	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—metabolic syndrome X	9.85e-06	0.000238	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—metabolic syndrome X	9.84e-06	0.000238	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LIPC—metabolic syndrome X	9.83e-06	0.000238	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCK—metabolic syndrome X	9.83e-06	0.000238	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOC3—metabolic syndrome X	9.77e-06	0.000236	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—metabolic syndrome X	9.69e-06	0.000234	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CETP—metabolic syndrome X	9.49e-06	0.000229	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	9.45e-06	0.000229	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—metabolic syndrome X	9.37e-06	0.000226	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCA1—metabolic syndrome X	9.34e-06	0.000226	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A4—metabolic syndrome X	9.34e-06	0.000226	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—INS—metabolic syndrome X	9.19e-06	0.000222	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SCARB1—metabolic syndrome X	9.08e-06	0.00022	CbGpPWpGaD
Valsartan—ALB—Metabolism—GGT1—metabolic syndrome X	9.05e-06	0.000219	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT1—metabolic syndrome X	9.05e-06	0.000219	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—metabolic syndrome X	8.94e-06	0.000216	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	8.85e-06	0.000214	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SREBF1—metabolic syndrome X	8.82e-06	0.000213	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMGCR—metabolic syndrome X	8.58e-06	0.000207	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT2—metabolic syndrome X	8.58e-06	0.000207	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—metabolic syndrome X	8.42e-06	0.000204	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—metabolic syndrome X	8.06e-06	0.000195	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	7.74e-06	0.000187	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOB—metabolic syndrome X	7.68e-06	0.000186	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	7.65e-06	0.000185	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	7.65e-06	0.000185	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—metabolic syndrome X	7.6e-06	0.000184	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—metabolic syndrome X	7.51e-06	0.000182	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G4A—metabolic syndrome X	7.47e-06	0.000181	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT1—metabolic syndrome X	7.41e-06	0.000179	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GGT1—metabolic syndrome X	7.41e-06	0.000179	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—metabolic syndrome X	7.37e-06	0.000178	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—metabolic syndrome X	7.33e-06	0.000177	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD36—metabolic syndrome X	6.97e-06	0.000168	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—metabolic syndrome X	6.48e-06	0.000157	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOB—metabolic syndrome X	6.28e-06	0.000152	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—metabolic syndrome X	6.27e-06	0.000152	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—metabolic syndrome X	6.14e-06	0.000149	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	6.11e-06	0.000148	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA1—metabolic syndrome X	6.07e-06	0.000147	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—metabolic syndrome X	6e-06	0.000145	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—metabolic syndrome X	5.73e-06	0.000138	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD36—metabolic syndrome X	5.7e-06	0.000138	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—metabolic syndrome X	5.51e-06	0.000133	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—metabolic syndrome X	5.35e-06	0.000129	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—metabolic syndrome X	5.3e-06	0.000128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—metabolic syndrome X	5.28e-06	0.000128	CbGpPWpGaD
Valsartan—ALB—Metabolism—INS—metabolic syndrome X	5.25e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—metabolic syndrome X	5.22e-06	0.000126	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—metabolic syndrome X	5.13e-06	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—metabolic syndrome X	5.03e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA1—metabolic syndrome X	4.97e-06	0.00012	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—metabolic syndrome X	4.6e-06	0.000111	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—metabolic syndrome X	4.38e-06	0.000106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—INS—metabolic syndrome X	4.3e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—metabolic syndrome X	4.21e-06	0.000102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—metabolic syndrome X	3.94e-06	9.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—metabolic syndrome X	3.77e-06	9.11e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—metabolic syndrome X	3.7e-06	8.95e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	3.45e-06	8.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—metabolic syndrome X	2.12e-06	5.12e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—metabolic syndrome X	1.73e-06	4.19e-05	CbGpPWpGaD
